{"id":"W4289522686","doi":"10.1182/blood.2021014586","title":"Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed <i>FLT3</i>mut+ AML ineligible for intensive chemotherapy","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Astellas Pharma","keywords":"Medicine; Internal medicine; Hazard ratio; Gastroenterology; Azacitidine; Chemotherapy; Interim analysis; Neutropenia; Adverse effect; Surgery; Chemotherapy regimen; Randomized controlled trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001703369,0.001136421,0.002366107,0.0003362654,0.0004275709,0.001029545,0.000800122,0.001472046,0.004571707],"category_scores_gemma":[0.001224481,0.0004026084,0.002218316,0.0002853207,0.000832317,0.0007471762,0.0003543945,0.003514489,0.0007188661],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009394515,"about_ca_system_score_gemma":0.001331459,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001155324,"about_ca_topic_score_gemma":0.003296063,"domain_scores_codex":[0.9996363,0.0001988924,0.00001490075,0.00005580296,0.00002453707,0.00006956975],"domain_scores_gemma":[0.999081,0.0002441439,0.0002100473,0.00006513132,0.00003941578,0.0003601305],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.961288,0.008205752,0.00111635,0.0003280955,0.0008729156,0.00008433548,0.00007418812,0.001023566,0.005819446,0.0002054177,0.002234259,0.01874766],"study_design_scores_gemma":[0.9030454,0.09003391,0.003496149,0.00003646197,0.0004407834,0.0000846464,0.00002468251,0.001065042,0.0006649506,0.0002990508,0.0007911669,0.00001775426],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897764,0.002960936,0.0004900584,0.0009638334,0.0004014228,0.002121901,0.001047749,0.0001554196,0.002082448],"genre_scores_gemma":[0.989409,0.001257206,0.001316723,0.001644425,0.0003262087,0.002474134,0.001669222,0.0000310869,0.001872094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004571707,"threshold_uncertainty_score":0.0152939,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03798504492468324,"score_gpt":0.3428577901550158,"score_spread":0.3048727452303326,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}